Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MDxHealth SA Announces Positive Data From Blinded Multicenter Clinical Study-Hugin


Monday, 11 Feb 2013 02:00am EST 

Hugin reported that MDxHealth SA announced the publication of results from a clinical study on its epigenetic ConfirmMDxTM for Prostate Cancer test in the March 2013 issue of Journal of Urology. The results demonstrate the utility of the ConfirmMDx test as a tool to address well-documented concerns over false-negative biopsy results.The blinded, multi center study named MATLOC (Methylation Analysis To Locate Occult Cancer), was conducted at University of Edinburgh Urological Cancer Group in the United Kingdom, the University Hospital of Liege, Belgium and the Institut de Genetique et Pathologie in Gosselies, Belgium. The investigators compared the performance of the ConfirmMDx assay to the current standard of care for men with -risk clinical factors for prostate cancer, but negative biopsy results. Archived tissue samples from previous negative biopsies of 483 men at high risk were tested with the ConfirmMDx assay. The ConfirmMDx test results were then compared to the cancer detection rate in the repeat biopsies conducted on the same patients within 30 months. 

Company Quote

4.573
-0.017 -0.37%
4:22am EST